Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents
ChemMedChem · 2025
DOI: 10.1002/cmdc.202400533 ↗At a glance
Journal article in ChemMedChem, 2025. Written by Keamogetswe Sechoaro and 5 co-authors. Institution: Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, 11 Hoffmann Street, Potchefstroom, 2…. Major MEDLINE topics: Parasitic Sensitivity Tests, Antiprotozoal Agents. Cited 5 times so far (Crossref); 71 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Research Foundation (NRF), North-West University, Potchefstroom Campus, Japan Society for the Promotion of Science (JSPS), KAKENHI.
Abstract (original language)
Neglected tropical diseases are a group of infectious diseases with a high endemicity in developing countries of Africa, Asia, and the Americas. Treatment for these diseases depends solely on chemotherapy, which is associated with severe side effects, toxicity, and the development of parasitic resistance. This highlights a critical need to develop new and effective drugs to curb these diseases. As a result, a series of novel isatinylhydantoin derivatives were synthesized and evaluated for in vitro anti ‐ kinetoplastid activity against seven human‐ or animal‐infective Trypanosoma and two human‐infective Leishmania species. The synthesized derivatives were tested for potential cytotoxicity against human, animal, and parasite host‐related cell lines. The isatinylhydantoin hybrid 4 b bearing 5‐chloroisatin and p ‐bromobenzyl moieties, showed strong trypanocidal activity against blood‐stage T. congolense parasites; however, the promising in vitro trypanocidal potency of 4 b could not be translated to in vivo treatment efficacy in a preliminary animal study. Compounds 5 , 2 b , and 5 b , were the most active against amastigotes of L. donovani , showing higher leishmanicidal activity than the reference drug, amphotericin B. These compounds were identified as early antileishmanicidal leads, and future investigations will focus on confirming their antileishmanial potential through in vivo efficacy evaluation as well as their exact mechanism of action.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Faculty of Health Sciences, North-West University, 11 Hoffmann Street, Potchefstroom, 2520, South Africa.
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Inada, Obihiro, Hokkaido, 080-8555, Japan.
ORCID profiles: Keamogetswe Sechoaro, Janine Aucamp, Christina Kannigadu, Helena D Janse van Rensburg, Keisuke Suganuma, David D N'Da
Funding
- National Research Foundation (NRF)
- North-West University, Potchefstroom Campus
- Japan Society for the Promotion of Science (JSPS), KAKENHI
- [Grants-in-Aid for Young Scientists (B)
- Ohyama Health Foundation, Inc.
Cite
APA
Sechoaro, K., Aucamp, J., Kannigadu, C., Janse van Rensburg, H. D., Suganuma, K., & N'Da, D. D. (2025). Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents. ChemMedChem. https://doi.org/10.1002/cmdc.202400533
Vancouver
Sechoaro K, Aucamp J, Kannigadu C, Janse van Rensburg HD, Suganuma K, N'Da DD. Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents. ChemMedChem. 2025. doi:10.1002/cmdc.202400533
BibTeX
@article{Sechoaro2025,
author = {Sechoaro, Keamogetswe and Aucamp, Janine and Kannigadu, Christina and Janse van Rensburg, Helena D and Suganuma, Keisuke and N'Da, David D},
title = {Investigation of Novel Isatinylhydantoin Derivatives as Potential Anti‐Kinetoplastid Agents},
journal = {ChemMedChem},
year = {2025},
doi = {10.1002/cmdc.202400533}
}
EUVIMED